As previously reported, the Federal Court of Appeal dismissed two decisions relating to paliperidone palmitate (Janssen’s INVEGA SUSTENNA), finding in a summary trial that each of Pharmascience and Apotex would induce infringement of Janssen’s patent.
In the Apotex case, the Federal Court of Appeal rejected Apotex’s argument that prescribing practices must be altered due to Apotex’s activities, as even if prescribing practices remained unchanged, activities by patients would be infringing once the product was sourced from Apotex. The Federal Court relied on several instances in the Apotex product monograph to support its finding of influence and was entitled to conclude that inducement would occur.
In the Pharmascience case, the Federal Court of Appeal rejected Pharmascience’s argument that since one of the doses that was part of the claimed dosage regimen would only be sourced from Janssen, Pharmascience’s activities would be licensed.
On June 27, 2024, the Supreme Court of Canada dismissed Apotex and Pharmascience’s applications for leave to appeal (Docket Nos. 41162 and 41164).
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Federal Court finds patent for concentrated methotrexate solutions obvious
On March 26, 2024, the Federal Court dismissed Medexus and Medac’s action for patent infringement of Canadian Patent No 2,659,662, finding the asserted claims invalid for obviousness: Medexus Pharmace...Read More -
Federal Court of Appeal upholds invalidity of Lilly’s CIALIS patent extending to “physiologically acceptable salt”
The Federal Court of Appeal dismissed an appeal by Lilly from a decision of the Federal Court which had granted a motion for summary trial brought by Teva, Pharmascience, Laboratoire Riva, Apotex and ...Read More -
Supreme Court of Canada dismisses Apotex’s application for leave to appeal macitentan inducing infringement decision
On June 6, 2024, the Supreme Court of Canada dismissed Apotex’s application for leave to appeal (Docket No. 41087).Read More